Alexion's Ultomiris and Soliris launch results

Alexion, a global biopharmaceutical company, announced its first quarter earnings last week which included numbers on its recent launches of Ultomiris, a new treatment option for adult patients living with paroxysmal nocturnal hemoglobinuria (PNH) and Soliris, as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive.

As of April 22, 22% of US patients with PNH had moved from using Soliris to Ultomiris. And in what is being called “its best launch ever”, almost 1,000 gMG patients were taking Soliris at the end of the first quarter, a number that implies 38% quarter-over-quarter growth.

Click here to read the entire article.